Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Pharmaceutical company of Pfizer in Pearl River, New York, NY, 10965, USA.
J Immunother Cancer. 2019 Jun 17;7(1):154. doi: 10.1186/s40425-019-0631-z.
Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how to achieve a survival-associated immune profile remains to be evaluated.
We analyzed datasets from The Cancer Genome Atlas to identify an immune profile associated with prolonged overall survival in multiple tumor types and tested the efficacy of tumor cell-surface vimentin-targeted interleukin 12 (ttIL-12) in inducing that immune profile and prolonging survival in both mouse and patient-derived xenograft tumor models.
We identified an immune profile (IFNγCD8FOXP3CD33) associated with prolonged overall survival across several human tumor types. ttIL-12 in combination with surgical resection of the primary tumor transformed tumors to this immune profile. Intriguingly, this immune profile transformation led to inhibition of metastasis and to prolonged survival in both mouse and patient-derived xenograft malignant models. Wild-type IL-12 combined with surgery was significantly less effective. In the IL-12-sensitive C3H mouse strain, in fact, wild-type IL-12 and surgery resulted in shorter overall survival than in mice treated with control pDNA; this surprising result is believed to be attributable to IL-12 toxicity, which was absent in the mice treated with ttIL-12. The ttIL-12-induced immune profile associated with longer overall survival was also associated with a greater accumulation of CD8 T cells and reduced infiltration of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. The underlying mechanism for this transformation by ttIL-12 treatment was induction of expression of CXCL9 and reduction of expression of CXCL2 and CCL22 in tumors.
ttIL-12 when combined with surgery led to conversion to the IFNγCD8FOXP3CD33 immune profile, eliminated relapse and metastasis, and prolonged overall survival.
尽管积累的证据为利用免疫谱预测癌症患者的生存提供了强有力的科学依据,但仍然缺乏跨肿瘤类型的通用免疫谱,如何实现与生存相关的免疫谱仍有待评估。
我们分析了来自癌症基因组图谱的数据集,以确定与多种肿瘤类型的总生存期延长相关的免疫谱,并在小鼠和患者来源的异种移植肿瘤模型中测试了靶向肿瘤细胞表面波形蛋白的白细胞介素 12(ttIL-12)诱导该免疫谱和延长生存的效果。
我们确定了一种与几种人类肿瘤类型的总生存期延长相关的免疫谱(IFNγCD8FOXP3CD33)。ttIL-12 与原发性肿瘤的手术切除联合使用可将肿瘤转化为该免疫谱。有趣的是,这种免疫谱的转化导致了转移的抑制和在小鼠和患者来源的异种移植恶性模型中的生存延长。野生型 IL-12 联合手术的效果明显较差。在 IL-12 敏感的 C3H 小鼠品系中,实际上,野生型 IL-12 和手术导致的总生存期比用对照 pDNA 治疗的小鼠更短;这一令人惊讶的结果据信归因于 IL-12 的毒性,而在用 ttIL-12 治疗的小鼠中则不存在。与更长的总生存期相关的 ttIL-12 诱导的免疫谱也与 CD8 T 细胞的更多积累和调节性 T 细胞、髓源性抑制细胞和肿瘤相关巨噬细胞的浸润减少相关。ttIL-12 治疗诱导这种转化的潜在机制是肿瘤中 CXCL9 的表达增加和 CXCL2 和 CCL22 的表达减少。
ttIL-12 与手术联合使用可导致向 IFNγCD8FOXP3CD33 免疫谱转化,消除复发和转移,并延长总生存期。